Journal of Bone and Mineral Research · 2016 · 79 citations · 48 references
MedicineCell BiologyPharmacologyBone MetabolismCell SignalingSignal TransductionBone DevelopmentBone FormationBone HealthOsteoclast BiologyOsteoclast FunctionOsteoporosisNf-κb SignalingNfatc1 ActivationNfatc1 RegulationOsteoclast InhibitionOsteoclast PrecursorsOsteoclast RegulationPostmenopausal Osteoporosis TreatmentProteasomal Turnover
ABSTRACT Given the limitations of current therapeutic options for postmenopausal osteoporosis, there is a need for alternatives with minimal adverse effects. In this study, we evaluated the effects of icaritin (ICT), a natural prenylflavonoid, on osteoclastogenesis both in vitro and in an ovariectomized (OVX) rat model and investigated its underlying molecular mechanism(s) of action. ICT inhibited osteoclast formation in two osteoclast precursor models, RAW 264.7 mouse monocyte cell line and human PBMC. ICT also inhibited sealing zone and resorption pit formation in a dose-dependent manner. Mechanistically, ICT inhibited RANKL-induced NF-κB and MAPK/AP-1 pathways to suppress gene expression of nuclear factor of activated T cells (NFAT)c1, the master transcription regulator of osteoclast differentiation. ICT, by inhibiting the TRAF6/c-Src/PI3K pathway, suppressed NADPH oxidase-1 activation to attenuate intracellular ROS production and downregulate calcineurin phosphatase activity. As a result, NFATc1 nuclear translocation and activity was suppressed. Crucially, ICT promoted proteasomal degradation of TRAF6, the critical adaptor protein that transduces RANKL/RANK signaling, and the inhibitory effect of ICT on osteoclastogenesis was reversed by the proteasomal inhibitor MG 132. ICT administration inhibited OVX-induced bone loss and resorption by suppressing osteoclast formation and activity. Consistent with cellular studies, ICT downregulated TRAF6 and NFATc1 protein expression in CD11b+/Gr-1-/low osteoclast precursors isolated from OVX rats. Put together, we present novel findings that ICT, by downregulating TRAF6, coordinates inhibition of NF-κB, MAPK/AP-1, and ROS signaling pathways to reduce expression and activity of NFATc1. These results demonstrate the potential of ICT for treatment of postmenopausal osteoporosis and point to TRAF6 as a promising target for novel anti-osteoporotic drugs. © 2017 American Society for Bone and Mineral Research.
48
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
Hiroshi Takayanagi, Kouetsu Ogasawara, Shigeaki Hida et al. · Nature · 2000 · 1.4K citations
Medicine, Cell Biology, Immunology +12
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Mark Lomaga, Wen‐Chen Yeh, Ildiko Sarosi et al. · Genes & Development · 1999 · 1.3K citations · Full text
Requirement for NF-κB in osteoclast and B-cell development
Guido Franzoso, Louise Carlson, Lianping Xing et al. · Genes & Development · 1997 · 994 citations · Full text
A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation
Na Kyung Lee, Young Geum Choi, Ji Youn Baik et al. · Blood · 2005 · 952 citations · Full text